AR051334A1 - Derivados de 2- amido-4-feniltiazol - Google Patents

Derivados de 2- amido-4-feniltiazol

Info

Publication number
AR051334A1
AR051334A1 ARP050104349A ARP050104349A AR051334A1 AR 051334 A1 AR051334 A1 AR 051334A1 AR P050104349 A ARP050104349 A AR P050104349A AR P050104349 A ARP050104349 A AR P050104349A AR 051334 A1 AR051334 A1 AR 051334A1
Authority
AR
Argentina
Prior art keywords
alkyl
alkoxy
group
cycloalkyl
trifluoro
Prior art date
Application number
ARP050104349A
Other languages
English (en)
Spanish (es)
Inventor
Pierre Casellas
Daniel Floutard
Pierre Lionel Fraisse
Samir Jegham
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of AR051334A1 publication Critical patent/AR051334A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ARP050104349A 2004-10-19 2005-10-18 Derivados de 2- amido-4-feniltiazol AR051334A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0411083A FR2876692B1 (fr) 2004-10-19 2004-10-19 Derives de 2-amido-4-phenylthiazole, leur preparation et leur application en therapeutique

Publications (1)

Publication Number Publication Date
AR051334A1 true AR051334A1 (es) 2007-01-03

Family

ID=34950743

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050104349A AR051334A1 (es) 2004-10-19 2005-10-18 Derivados de 2- amido-4-feniltiazol

Country Status (27)

Country Link
US (1) US7598392B2 (enExample)
EP (1) EP1807421B1 (enExample)
JP (1) JP2008517042A (enExample)
KR (1) KR20070085395A (enExample)
CN (1) CN101065376A (enExample)
AR (1) AR051334A1 (enExample)
AT (1) ATE502035T1 (enExample)
AU (1) AU2005296958A1 (enExample)
BR (1) BRPI0518231A2 (enExample)
CA (1) CA2584774A1 (enExample)
DE (1) DE602005026964D1 (enExample)
EA (1) EA200700901A1 (enExample)
EC (1) ECSP077402A (enExample)
FR (1) FR2876692B1 (enExample)
GT (1) GT200500292A (enExample)
IL (1) IL182624A0 (enExample)
MA (1) MA29017B1 (enExample)
MX (1) MX2007004740A (enExample)
NO (1) NO20072515L (enExample)
PA (1) PA8649901A1 (enExample)
PE (1) PE20060585A1 (enExample)
SV (1) SV2006002274A (enExample)
TN (1) TNSN07145A1 (enExample)
TW (1) TW200630364A (enExample)
UY (1) UY29169A1 (enExample)
WO (1) WO2006042954A1 (enExample)
ZA (1) ZA200703876B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2854158B1 (fr) 2003-04-25 2006-11-17 Sanofi Synthelabo Derives de 2-acylamino-4-phenylethiazole, leur preparation et leur application en therapeutique
FR2872813B1 (fr) 2004-07-09 2007-01-19 Sanofi Synthelabo Derives de 2-carbamide-4-phenylthiazole, leur preparation et leur application en therapeutique
RU2008128453A (ru) 2005-12-12 2010-01-20 Дженелабс Текнолоджис, Инк. (Us) Соединение n-(5-членных арил)-амидов, фармацевтическая композиция с противовирусной активностью на их основе, способ лечения или профилактики вирусной инфекции с их помощью и способ их получения
FR2895989B1 (fr) 2006-01-06 2010-04-30 Sanofi Aventis Derives de 2-carbamide-4-phenylthiazole, leur preparation et leur application en therapeutique
US20100331298A1 (en) * 2007-12-10 2010-12-30 Cytopathfinder, Inc. Carboxamide Compounds and Their Use
AU2008335135A1 (en) 2007-12-11 2009-06-18 Cytopathfinder, Inc. Carboxamide compounds and their use as chemokine receptor agonists
EP2349484A2 (en) 2008-07-15 2011-08-03 Novartis AG Heteroaryl derivatives as dgat1 inhibitors
JP5819730B2 (ja) * 2008-12-22 2015-11-24 ケモセントリックス,インコーポレイティド C5aRアンタゴニスト
CN103402996B (zh) 2011-01-04 2015-02-11 诺瓦提斯公司 可用于治疗年龄相关性黄斑变性(amd)的吲哚化合物或其类似物
JP6209605B2 (ja) 2012-06-28 2017-10-04 ノバルティス アーゲー ピロリジン誘導体、および補体経路調節因子としてのその使用
CN104619698B (zh) 2012-06-28 2016-08-31 诺华股份有限公司 吡咯烷衍生物及其作为补体途径调节剂的用途
WO2014002051A2 (en) 2012-06-28 2014-01-03 Novartis Ag Complement pathway modulators and uses thereof
CN104640855B (zh) 2012-06-28 2017-08-29 诺华股份有限公司 补体途经调节剂及其用途
EP2867229B1 (en) 2012-06-28 2017-07-26 Novartis AG Pyrrolidine derivatives and their use as complement pathway modulators
US9550755B2 (en) 2012-07-12 2017-01-24 Novartis Ag Complement pathway modulators and uses thereof
AR121506A1 (es) 2020-03-03 2022-06-08 Pic Therapeutics Inc Inhibidores del eif4e y sus usos
US12157732B2 (en) 2021-08-25 2024-12-03 PIC Therapeutics, Inc. eIF4E inhibitors and uses thereof
IL310924A (en) 2021-08-25 2024-04-01 Pic Therapeutics Inc Eif4e inhibitors and uses thereof
KR20240140019A (ko) * 2023-03-15 2024-09-24 현대약품 주식회사 신규한 화합물, 및 이를 포함하는 약학적 조성물
WO2026054614A1 (ko) * 2024-09-09 2026-03-12 현대약품 주식회사 신규한 화합물, 및 이를 포함하는 약학적 조성물

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2146898A (en) * 1937-12-06 1939-02-14 Int Harvester Co Potato digger
FR2406634A1 (fr) * 1977-10-19 1979-05-18 Fabre Sa Pierre Immunostimulants derives d'amino thiazoles
FR2677356B1 (fr) 1991-06-05 1995-03-17 Sanofi Sa Derives heterocycliques d'acylamino-2 thiazoles-5 substitues, leur preparation et compositions pharmaceutiques en contenant.
EP0589985A1 (en) 1991-06-21 1994-04-06 Boehringer Mannheim Italia S.P.A. 2-amino-4-aryl-thiazoles with antiasthmatic and anti-inflammatory activities on the respiratory tract
US6506751B1 (en) * 1999-11-12 2003-01-14 Millennium Pharmaceuticals, Inc. Thiazolidinone compounds useful as chemokine inhibitors
US6852752B2 (en) * 1999-12-17 2005-02-08 Vicuron Pharmaceuticals Inc. Urea compounds, compositions and methods of use and preparation
US6797820B2 (en) * 1999-12-17 2004-09-28 Vicuron Pharmaceuticals Inc. Succinate compounds, compositions and methods of use and preparation
CN1289072C (zh) * 2000-12-22 2006-12-13 石原产业株式会社 苯胺衍生物或其盐以及含有它们的细胞因子产生抑制剂
US7265134B2 (en) 2001-08-17 2007-09-04 Merck & Co., Inc. Tyrosine kinase inhibitors
TW200403058A (en) * 2002-04-19 2004-03-01 Bristol Myers Squibb Co Heterocyclo inhibitors of potassium channel function
FR2854158B1 (fr) * 2003-04-25 2006-11-17 Sanofi Synthelabo Derives de 2-acylamino-4-phenylethiazole, leur preparation et leur application en therapeutique
TW200423931A (en) 2003-04-30 2004-11-16 Hoffmann La Roche Novel aniline derivatives, their manufacture and use as pharmaceutical agents
FR2872813B1 (fr) * 2004-07-09 2007-01-19 Sanofi Synthelabo Derives de 2-carbamide-4-phenylthiazole, leur preparation et leur application en therapeutique
CA2589748C (en) 2004-12-24 2013-08-13 Astrazeneca Ab Heterocyclic compounds as ccr2b antagonists
FR2895989B1 (fr) 2006-01-06 2010-04-30 Sanofi Aventis Derives de 2-carbamide-4-phenylthiazole, leur preparation et leur application en therapeutique

Also Published As

Publication number Publication date
KR20070085395A (ko) 2007-08-27
IL182624A0 (en) 2007-07-24
FR2876692A1 (fr) 2006-04-21
PA8649901A1 (es) 2006-06-02
GT200500292A (es) 2006-05-11
NO20072515L (no) 2007-06-28
EA200700901A1 (ru) 2007-10-26
EP1807421A1 (fr) 2007-07-18
TW200630364A (en) 2006-09-01
WO2006042954A8 (fr) 2008-03-13
UY29169A1 (es) 2006-05-31
CN101065376A (zh) 2007-10-31
CA2584774A1 (fr) 2006-04-27
WO2006042954A1 (fr) 2006-04-27
EP1807421B1 (fr) 2011-03-16
FR2876692B1 (fr) 2007-02-23
ECSP077402A (es) 2007-05-30
JP2008517042A (ja) 2008-05-22
MX2007004740A (es) 2007-06-18
SV2006002274A (es) 2006-06-28
PE20060585A1 (es) 2006-08-18
ATE502035T1 (de) 2011-04-15
MA29017B1 (fr) 2007-11-01
DE602005026964D1 (de) 2011-04-28
BRPI0518231A2 (pt) 2008-11-11
US7598392B2 (en) 2009-10-06
US20070259847A1 (en) 2007-11-08
AU2005296958A1 (en) 2006-04-27
ZA200703876B (en) 2008-12-31
TNSN07145A1 (fr) 2008-11-21

Similar Documents

Publication Publication Date Title
AR087328A1 (es) Derivados de imidazo[1,2-b]piridazina e imidazo[4,5-b]piridina como inhibidores de jak
AR120855A1 (es) Derivados de pirazolilo útiles como agentes anticancerígenos
AR063318A1 (es) Pirazoliltienopiridinas terapeuticas
AR036107A1 (es) Derivados de 6-fenilpirrolpirimidindiona, antagonista de los receptores a2 de la adenosina, particularmente del subtipo a2, de aplicacion en la prevencion de la degranulacion de los mastocitos; composiciones farmaceuticas formuladas con dichos compuestos y uso de los mismos en la preparacion de medi
ECSP045368A (es) "antagonistas de los receptores de trombina"
AR053652A1 (es) Derivados de indol como inhibidores de proteina quinasas. composiciones farmaceuticas
AR053195A1 (es) Compuestos inhibidores de dipeptidil peptidasa-iv metodos para preparar los mismos y composiciones farmaceuticas que los contienen como un agente activo
AR044614A1 (es) Composiciones de sulfonamida que modulan la actividad del receptor de quinioquinas (ccr4)
ES2530943T3 (es) Derivados de la cromenona con actividad antitumoral
AR044874A1 (es) Derivados de 4- cianopirazol-3 - carboxamida, su preparacion y su aplicacion en terapeutica
AR060593A1 (es) 5-amido-2-carboxiamida-indoles
AR046711A1 (es) 5-7-diaminopirazolo[4,3d]pirimidinas como inhibidores de la pde-5,composiciones farmaceuticas que las contienen y usos en el tratamiento de hipertensiones
AR059184A1 (es) Derivados de sulfonamidas, su preparacion y su aplicacion en tarapeutica
AR085615A1 (es) Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen
AR078168A1 (es) Derivados de piperidinas y piperazinas, procesos para prepararlos y sus usos como moduladores de gpr119
CO6321130A2 (es) Piridinas carboxamidas como inhibidores de la 11 beta-hsd1
AR038000A1 (es) Compuesto derivado de tien[2,3-d]pirimidin-2,4(1h,3h)-diona, composicion farmaceutica, proceso para su preparacion y su uso en la fabricacion de un medicamento
AR079231A1 (es) Derivados de imidazoquinolina
AR052943A1 (es) Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida
AR081932A1 (es) Derivados de heteroaril imidazolona, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades neoplasicas y autoinmunes
AR066669A1 (es) Derivados de imidazolona como inhibidores de bencimidazolona quimasa. composiciones farmaceuticas.
AR042668A1 (es) Derivados de fosfonoxi quinazolinas y su uso farmaceutico
AR047056A1 (es) Derivados de pirimidinas condensadas. composiciones farmacéuticas
AR037907A1 (es) Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6
AR081252A1 (es) Compuestos para el tratamiento del sindrome metabolico

Legal Events

Date Code Title Description
FB Suspension of granting procedure